Ulrike Weyer-Czernilofsky

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 3

Top Topics

Prostate Cancer

Radical Prostatectomy

Dna Damage Response

Endoplasmic Reticulum Stress

Top Venues

Molecular cancer therapeutics

Cancer research

This page only lists publications with an associated author ORCID identifier.

Publications

Andreas Gollner, Dorothea Rudolph, Ulrike Weyer-Czernilofsky, Rosa Baumgartinger, Peter Jung, Harald Weinstabl, Juergen Ramharter, Rolf Grempler, Jens Quant, Joerg Rinnenthal, Alejandro Pérez Pitarch, Bojana Golubovic, Daniel Gerlach, Gerd Bader, Kristiane Wetzel, Sebastian Otto, Christian Mandl, Guido Boehmelt, Darryl B McConnell, Norbert Kraut, Patrizia Sini
Discovery and Characterization of Brigimadlin, a Novel and Highly Potent MDM2-p53 Antagonist Suitable for Intermittent Dose Schedules. Molecular cancer therapeutics (2024)
Guillaume Rieunier, Xiaoning Wu, Letitia E Harris, Jack V Mills, Ashwin Nandakumar, Laura Colling, Elena Seraia, Stephanie B Hatch, Daniel V Ebner, Lisa K Folkes, Ulrike Weyer-Czernilofsky, Thomas Bogenrieder, Anderson J Ryan, Valentine M Macaulay
Targeting IGF Perturbs Global Replication through Ribonucleotide Reductase Dysfunction. Cancer research 81 (8) (2021)
Ulrike Weyer-Czernilofsky, Marco H Hofmann, Katrin Friedbichler, Rosa Baumgartinger, Paul J Adam, Flavio Solca, Norbert Kraut, Holly M Nguyen, Eva Corey, Gang Liu, Cynthia C Sprenger, Stephen R Plymate, Thomas Bogenrieder
Antitumor Activity of the IGF-1/IGF-2-Neutralizing Antibody Xentuzumab (BI 836845) in Combination with Enzalutamide in Prostate Cancer Models. Molecular cancer therapeutics 19 (4) (2020)